

---

**TABLE OF CONTENTS**

<b>1</b>	<b><i>INTRODUCTION AND OBJECTIVES</i></b> .....	<b>1</b>
1.1	<i>Introduction</i>	1
1.2	<i>Objectives</i>	3
<b>2</b>	<b><i>THEORETICAL BACKGROUND</i></b> .....	<b>4</b>
2.1	<i>Cyclosporin A</i>	4
2.1.1	<i>The history of cyclosporin A</i>	4
2.1.2	<i>Chemistry of cyclosporin</i>	8
2.1.3	<i>Mechanism of action</i>	9
2.1.4	<i>Cyclosporin A formulation and bioavailability</i>	11
2.2	<i>Pulmonary application</i>	13
2.2.1	<i>Lung anatomy and physiology</i>	13
2.2.2	<i>Pulmonary barriers and defense mechanisms</i>	15
2.2.3	<i>Particle deposition in the respiratory tract</i>	16
2.3	<i>Pharmaceutical aerosols</i>	18
2.3.1	<i>Development of inhalation drug delivery</i>	18
2.3.2	<i>Description of aerosol particle size</i>	20
2.3.3	<i>Pulmonary delivery of therapeutic peptides and proteins</i>	22
2.4	<i>Nebulization drug delivery</i>	25
2.4.1	<i>Historical perspective</i>	25
2.4.2	<i>Nebulization techniques</i>	26
2.4.3	<i>Nebulizer performance</i>	31
2.4.4	<i>Nebulizer solution and suspension formulations</i>	33
2.4.5	<i>Factors affecting nebulizer performance</i>	34
<b>3</b>	<b><i>EXPERIMENTAL METHODS</i></b> .....	<b>37</b>
3.1	<i>Cyclosporin A characterization</i>	37
3.1.1	<i>Physicochemical characterization</i>	37

---

3.1.2	<i>CsA analysis</i>	39
3.2	<i>CsA suspensions</i>	40
3.2.1	<i>Preparation of CsA suspensions</i>	40
3.2.2	<i>Characterization of CsA suspensions</i>	41
3.3	<i>Aerosolization</i>	44
3.3.1	<i>Nebulization of CsA suspensions</i>	44
3.3.2	<i>Aerosol Performance characterization</i>	45
3.4	<i>Statistical analysis</i>	48
4	<i>CHARACTERIZATION OF CYCLOSPORIN A.....</i>	49
4.1	<i>CsA qualitative and quantitative analysis</i>	49
4.1.1	<i>CsA identification test</i>	49
4.1.2	<i>Qualitative analysis of CsA degradation products</i>	50
4.1.3	<i>Quantitative analysis of CsA</i>	51
4.2	<i>CsA physicochemical characteres</i>	52
4.2.1	<i>CsA hydrophobic character</i>	52
4.2.2	<i>CsA solubility</i>	53
4.2.3	<i>CsA crystal properties</i>	54
4.2.4	<i>CsA moisture content and water sorption character</i>	55
4.3	<i>CsA stability tests</i>	56
4.3.1	<i>Effect of pH-value</i>	56
4.3.2	<i>Effect of storage temperature</i>	57
4.3.3	<i>CsA light sensitivity</i>	58
5	<i>PREFORMULATION.....</i>	59
5.1	<i>CsA particle size reduction</i>	59
5.1.1	<i>CsA micronization</i>	59
5.1.2	<i>High pressure homogenization</i>	61
5.2	<i>Choice of excipients</i>	63

---

---

5.2.1	<i>Buffering system</i>	63
5.2.2	<i>Surfactant</i>	67
5.2.3	<i>Surfactant/co-surfactant combination</i>	72
5.2.4	<i>Long-term CsA preformulation stability</i>	80
5.2.5	<i>Addition of an excess of stabilizer</i>	81
6	<b>CYCLOSPORIN A MICROSUSPENSIONS.....</b>	<b>86</b>
6.1	<i>Formulation</i>	86
6.2	<i>Characterization</i>	86
6.3	<i>Stability studies</i>	88
6.4	<i>Nebulization studies</i>	90
6.4.1	<i>Inhalation time measurements</i>	90
6.4.2	<i>CsA output rate and residual amount</i>	92
6.4.3	<i>CsA delivery efficiency</i>	93
7	<b>METHOD OPTIMIZATION .....</b>	<b>95</b>
7.1	<i>In-situ-micronization</i>	95
7.2	<i>High pressure homogenization</i>	96
7.2.1	<i>Effect of homogenization pressure</i>	99
7.2.2	<i>Effect of temperature</i>	100
7.3	<i>Packaging of CsA nano-suspensions</i>	101
8	<b>CYCLOSPORIN A NANOSUSPENSIONS.....</b>	<b>103</b>
8.1	<i>CsA nano- and microsuspensions</i>	103
8.1.1	<i>Particle size measurements</i>	103
8.1.2	<i>Nebulization studies</i>	104
8.2	<i>Long-term stability studies</i>	108
9	<b>EFFECT OF VISCOSITY.....</b>	<b>111</b>
9.1	<i>Formulation</i>	111

---

<b>9.2</b>	<b><i>Characterization</i></b>	<b>111</b>
<b>9.3</b>	<b><i>Stability studies</i></b>	<b>113</b>
<b>9.4</b>	<b><i>Nebulization studies</i></b>	<b>114</b>
9.4.1	<i>Inhalation time measurements</i>	114
9.4.2	<i>CsA output rate and residual drug amount</i>	115
9.4.3	<i>CsA delivery efficiency</i>	117
<b>10</b>	<b><i>EFFECT OF SURFACE TENSION.....</i></b>	<b>119</b>
10.1	<i>Formulation</i>	119
10.2	<i>Characterization</i>	119
10.3	<i>Stability studies</i>	121
10.4	<i>Nebulization studies</i>	123
10.4.1	<i>Inhalation time measurements</i>	123
10.4.2	<i>CsA output rate and residual amount</i>	124
10.4.3	<i>CsA delivery efficiency</i>	127
<b>11</b>	<b><i>EFFECT OF CO-SURFACTANT.....</i></b>	<b>129</b>
11.1	<i>Formulation</i>	129
11.2	<i>Characterization</i>	129
11.3	<i>Stability studies</i>	131
11.4	<i>Nebulization studies</i>	132
11.4.1	<i>Inhalation time measurements</i>	133
11.4.2	<i>CsA output rate and residual amount</i>	134
11.4.3	<i>CsA delivery efficiency</i>	136
11.4.4	<i>Effect of nebulization on suspension particle size</i>	137
11.5	<i>Sterilization</i>	137
<b>12</b>	<b><i>CYCLODEXTRINS.....</i></b>	<b>140</b>
12.1	<i>Formulation</i>	140

---

<b>12.2 Characterization</b>	<b>140</b>
<b>12.3 Suspension particle size analysis</b>	<b>142</b>
<b>12.4 Nebulization studies</b>	<b>143</b>
12.4.1 Inhalation time measurements	143
12.4.2 CsA output rate and residual amount	144
12.4.3 CsA delivery efficiency	146
<b>13 NEBULIZER PERFORMANCE.....</b>	<b>148</b>
<b>13.1 Nebulizers used</b>	<b>148</b>
<b>13.2 Nebulization studies</b>	<b>148</b>
13.2.1 Inhalation time measurements	148
13.2.2 CsA output rate and residual amount	150
13.2.3 CsA delivery efficiency	152
<b>14 SUMMARY.....</b>	<b>154</b>
<b>15 ZUSAMMENFASSUNG.....</b>	<b>156</b>
<b>16 APPENDIX.....</b>	<b>159</b>
<b>16.1 Materials</b>	<b>159</b>
<b>16.2 List of Abbreviations</b>	<b>161</b>
<b>17 REFERENCES.....</b>	<b>163</b>
<b>ACKNOWLEDGEMENTS.....</b>	<b>180</b>
<b>CURRICULUM VITAE.....</b>	<b>182</b>

---